Document Detail

Immunosuppressive therapy is more effective than interferon in neuromyelitis optica.
MedLine Citation:
PMID:  17439893     Owner:  NLM     Status:  MEDLINE    
To determine long-term treatment (LTT) of neuromyelitis optica (NMO), we retrospectively reviewed therapies of 26 patients with NMO followed in five French neurological departments. To assess LTT efficacy, the probability of relapse free after LTT was analysed. Patients were divided into two groups according to the first treatment receiving interferon beta (IFN Group, seven patients) or immunosuppressants (IS Group, 19 patients). The probability of relapse was significantly lower in the IS Group (P =0.0007). From our results, interferon beta is not recommended, and one of the best current therapeutic options for NMO appears to be immunosuppressants.
C Papeix; J-S Vidal; J de Seze; C Pierrot-Deseilligny; A Tourbah; B Stankoff; C Lebrun; T Moreau; P Vermersch; B Fontaine; O Lyon-Caen; O Gout
Related Documents :
3609413 - Parenteral interferon-alpha treatment of psoriasis.
17530483 - Randomized phase ii trial of thalidomide alone versus thalidomide plus interferon alpha...
16291103 - Symptomatic cervical disc herniation following a motor vehicle collision: return to wor...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't     Date:  2007-01-29
Journal Detail:
Title:  Multiple sclerosis (Houndmills, Basingstoke, England)     Volume:  13     ISSN:  1352-4585     ISO Abbreviation:  Mult. Scler.     Publication Date:  2007 Mar 
Date Detail:
Created Date:  2007-04-18     Completed Date:  2007-06-14     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9509185     Medline TA:  Mult Scler     Country:  England    
Other Details:
Languages:  eng     Pagination:  256-9     Citation Subset:  IM    
Department of Neurology, Hôpital de la Salpêtrière, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Disease-Free Survival
Immunologic Factors / therapeutic use*
Immunosuppressive Agents / therapeutic use*
Interferon-beta / therapeutic use*
Kaplan-Meiers Estimate
Middle Aged
Neuromyelitis Optica / drug therapy*
Recurrence / prevention & control
Retrospective Studies
Treatment Outcome
Reg. No./Substance:
0/Immunologic Factors; 0/Immunosuppressive Agents; 77238-31-4/Interferon-beta

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Profile of cytokine gene polymorphisms in Iranian multiple sclerosis patients.
Next Document:  Epidemiology of familial multiple sclerosis in Hungary.